NPTX Neuropathix Inc

Neuropathix is a biopharmaceutical company focused on the research and development of next generation, breakthrough anti-inflammatory therapeutics. The company's subsidiary Kannalife Sciences developed their lead compound, KLS-13019 which has been extensively researched in preclinical and IND-enabling studies and found to be effective in the prevention and reversal of peripheral neuropathy. Kannalife’s research has been backed by a total of $3.3 million in grant funding from the National Institutes of Health (NIH) under the NIH HEAL Initiative and focused on the treatment of chemotherapy induced peripheral neuropathy (CIPN). KLS-13019 is part of a globally patented estate of new therapeutic synthetic cannabinoids designed by Kannalife, focused on neuroprotection and neuroinflammation. The company conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.